Skip to content

High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER) and Weight Loss

To Determine the Effect of PACER Diet (High Protein Atkin's Complete VEgetaRian Diet) in Obese Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02562209
Acronym
PACER
Enrollment
104
Registered
2015-09-29
Start date
2012-01-31
Completion date
2014-11-30
Last updated
2015-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, Abdominal adiposity, High protein diet

Brief summary

This study evaluates the effects High Protein Atkin's Complete (lacto) VEgetaRian Diet (Acronym; 'PACER' diet) on weight, body composition and metabolic profiles in obese Asian Indians subjects living in north India.

Detailed description

Increasing the protein consumption promotes weight loss through several mechanisms. Diets high in protein promote energy expenditure through increased postprandial thermogenesis, increase total daily expenditure and increase satiety as compared to carbohydrate. The present study aims to evaluate the effects High Protein Atkin's Complete (lacto) VEgetaRian Diet (Acronym; 'PACER' diet) on weight, body composition and metabolic profiles in obese Asian Indians subjects living in north India.

Interventions

DIETARY_SUPPLEMENTPACER Diet

Pacer diet to be followed for 8 weeks

OTHERStandard weight reducing diet

Standard weight reducing diet to be followed for 8 weeks

Sponsors

Diabetes Foundation, India
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age 25 to 60 years * Body mass index (BMI) ≥ 25 kg/m2 to 40 kg/m2 * Subjects who have stable weight, i.e. who have not had more than ± 3 kg variation in their weight level in the 3 months prior to screening for this study. * Absence of significant disease or clinically significant medical history or physical examination during screening in the view of the investigator. * Subjects willing to provide written inform consent to participate in the study.

Exclusion criteria

* Body mass index (BMI) \> 40 kg/m2 * Any patient taking/requiring drugs known to effect insulin resistance, lipids, vascular reactivity, during the intervention period would be excluded from the study * Patients on any drugs that change the weight or in conditions where dietary protein supplementation is contraindicated * Subjects who are consuming a high protein diet on randomization, to be excluded * Acute infections or chronic debilitating diseases like tuberculosis, malignancy, HIV infection etc * Any life threatening serious disorder of the liver, kidneys, heart, lungs or other organs * Pregnancy & lactation * Patients having diagnosed with any of the following: * Type 2 diabetes mellitus * Cushing's disease * Severe end organ damage * Unwillingness to give written informed consent for participation in the study

Design outcomes

Primary

MeasureTime frame
Weight loss (kg)8 weeks

Secondary

MeasureTime frame
Lipid profile8 weeks
Insulin resistance8 weeks

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026